The Coalition for Epidemic Preparedness Innovations (CEPI) will provide Novavax with up to $384 million in additional funding toward clinical development and large-scale manufacturing of the company’s COVID-19 vaccine candidate NVX-CoV2373, CEPI and the company said. Genetic Engineering & Biotechnology News (GEN)
Tuesday, May 12, 2020
CEPI Gives Novavax Up to $384M for COVID-19 Vaccine R&D, Manufacturing
The Coalition for Epidemic Preparedness Innovations (CEPI) will provide Novavax with up to $384 million in additional funding toward clinical development and large-scale manufacturing of the company’s COVID-19 vaccine candidate NVX-CoV2373, CEPI and the company said. Genetic Engineering & Biotechnology News (GEN)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment